ClinicalTrials.gg
CompletedNCT01429246CSSS-TibetUpdated Jul 29, 2016

China Salt Substitute Study in Tibet

An interventional study of Regular Salt and Salt Substitute in Hypertension, sponsored by The George Institute for Global Health, China. Completed at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-07-29.

Sponsored by The George Institute for Global Health, China · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Enrollment
140th of 308
282 · median 253
Started
2009
with 7 others
No phase
146 of 410
56 open now
Registered
48th of 410
by date
Lead sponsor
7 of 410
The George Institute for Global Health, China

Among the 410 studies in Hypertension with a site in China, this one is the 140th largest by enrollment of the 308 interventional ones that give a count, is one of 8 that started in 2009, is one of 146 with no phase, and was the 48th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

The study was a single-blind randomized controlled trial conducted between February and August 2009 in two townships (Yangbajing and Gongtang) of Dangxiong County, an area at 4300 meters altitude in Tibet. A brief baseline survey and assessment for eligibility was performed before randomization. A total of 282 residents with known hypertension (systolic blood pressure ≥ 140mmHg) were recruited and randomly assigned to intervention or control with stratification by gender and baseline blood pressure. The intervention group received 6-month's supply of salt substitute (68% sodium chloride, 22% potassium chloride and 10% magnesium sulfate heptahydrate) and the control group 6-month's supply of regular salt (100% sodium chloride). After 3-month's intervention, the ones with a blood pressure above 140 mmHg / 90 mmHg will be given low-dose diuretic for further anti-hypertensive therapy. The study hypothesis is that salt-substitute will greatly reduce blood pressure in treated patients when compared to controls. Blood pressure levels were measured at baseline and followed up by trained observers using an automated sphygmomanometer and brief survey on level of compliance, amount of salt consumed, and reasons for non-compliance.

Read the detailed description

Hypertension is one of the most important risk factors that induce cardiovascular and cerebrovascular disease. Reducing the blood pressure levels of population can not only control the incidence of cardiovascular and cerebrovascular disease effectively, but also reduce the mortality. Anti-hypertension drug therapy has been proven to be an effective method to reduce blood pressure. Dietary sodium restriction and potassium supplementation is the core of dietary approaches to stop hypertension. Tibet is located on the Tibetan Plateau with an average altitude about 4000 meters above sea level. Tibetan diet is rich in meat but poor in vegetables and fruits. Salt intake is quite high due to habitual drinking of salty butter tea. Former national surveys showed a high prevalence of hypertension in Tibet. The investigators conducted this randomized controlled intervention study to test whether the investigators can offer a cost effective way to lower blood pressure and control hypertension in a sample of subjects from Yangbajing and Gongtang in Dangxiong County, Lhasa, Tibet.

A randomized controlled trial was conducted in Yangbajing Township and Gongtang Village in the Dangxiong county , Tibet. A total of 282 hypertensive patients were chosen as study subjects. The regular salt or salt substitution were randomly allocated to the two groups. The whole intervention last for 6 months, with Phase 1 for three months and a following Phase 2 for another three months. For Phase 1, the study subjects were allocated the regular salt or the salt substitute after a randomization. For Phase 2, the study subjects continued the intervention of regular salt or salt substitute while the ones with a blood pressure above 140mmHg/90 mmHg will be given low-dose diuretic for further anti-hypertensive therapy. During the whole intervention period, the study subjects were not informed of what kind of salt they were taking. Blood pressure was the major outcome and would be measured at baseline, 3 months and 6 months.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Diet Therapy
  • Sodium Chloride, Dietary
  • Tibet
  • Aged
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40 years or older
  • Resident of Yangbajing Township and Gongtang Village in Tibetan Autonomous Region, People's Republic of China
  • Mean Systolic Hypertension (≥ 140 mmHg)

Exclusion criteria

Exclusion Criteria:

  • Currently taking any potassium supplements (or lives in household where someone does)
  • Previously diagnosed kidney disease or gout (or lives in a household where someone does) and physician considered he/she cannot take salt substitute.
  • Any person who intended to use salt outside the assigned treatment salt provide in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
282 participants (actual)

Study arms

  • Active comparator
    Normal Salt

    100% Sodium Chloride

    Dietary Supplement: Regular Salt

  • Experimental
    Salt Substitute

    65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)

    Dietary Supplement: Salt Substitute

Interventions

  • Dietary supplementRegular Salt

    Estimated Household Individual Consumption of 30 grams per day

  • Dietary supplementSalt Substitute

    Estimated 30 grams per day per household member

06

What researchers measure

Primary outcomes

  1. Change in Baseline Mean Systolic Blood Pressure (mmHg) at 6 months

    3 Serial in Right Arm with Seated Patients with at least 1 minute between measurements using Omron 751 Automated Cuff.

    Time frame: (Baseline compared to 6 months after start of intervention)

Secondary outcomes

  1. Percent of patients having blood pressure under control (<140/90 mmHg)

    Time frame: Baseline, and post start of intervention at 3 months and 6 months

  2. Change in Baseline Mean Systolic Blood Pressure (mmHg) at 3 months.

    3 Serial in Right Arm with Seated Patients with at least 1 minute between measurements using Omron 751 Automated Cuff

    Time frame: (Baseline compared to 3 months after start of intervention)

07

Study locations

1 site
  • Dangxiong People's Hospital
    Lhasa, Tibet 850000, China
08

References and documents

Publications

  • Tian HG, Guo ZY, Hu G, Yu SJ, Sun W, Pietinen P, Nissinen A. Changes in sodium intake and blood pressure in a community-based intervention project in China. J Hum Hypertens. 1995 Dec;9(12):959-68. PubMed 8746640 ↗
  • Hooper L, Bartlett C, Davey SG, Ebrahim S. Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev. 2004;(1):CD003656. doi: 10.1002/14651858.CD003656.pub2. PubMed 14974027 ↗
  • He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004;(3):CD004937. doi: 10.1002/14651858.CD004937. PubMed 15266549 ↗
  • China Salt Substitute Study Collaborative Group. Salt substitution: a low-cost strategy for blood pressure control among rural Chinese. A randomized, controlled trial. J Hypertens. 2007 Oct;25(10):2011-8. doi: 10.1097/HJH.0b013e3282b9714b. PubMed 17885542 ↗
  • Zhou X, Liu JX, Shi R, Yang N, Song DL, Pang W, Li YM. Compound ion salt, a novel low-sodium salt substitute: from animal study to community-based population trial. Am J Hypertens. 2009 Sep;22(9):934-42. doi: 10.1038/ajh.2009.135. Epub 2009 Aug 6. PubMed 19661926 ↗
  • He FJ, MacGregor GA. Can a low-sodium, high-potassium salt substitute reduce blood pressure in rural Chinese people? Nat Clin Pract Cardiovasc Med. 2008 Apr;5(4):186-7. doi: 10.1038/ncpcardio1122. Epub 2008 Jan 29. No abstract available. PubMed 18227813 ↗
  • Hu J, Jiang X, Li N, Yu X, Perkovic V, Chen B, Zhao L, Neal B, Wu Y. Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertens Res. 2009 Apr;32(4):282-8. doi: 10.1038/hr.2009.7. Epub 2009 Feb 27. PubMed 19262499 ↗
  • Li N, Prescott J, Wu Y, Barzi F, Yu X, Zhao L, Neal B; China Salt Substitute Study Collaborative Group. The effects of a reduced-sodium, high-potassium salt substitute on food taste and acceptability in rural northern China. Br J Nutr. 2009 Apr;101(7):1088-93. doi: 10.1017/S0007114508042360. Epub 2008 Aug 19. PubMed 18710605 ↗
  • Zhao X, Yin X, Li X, Yan LL, Lam CT, Li S, He F, Xie W, Sang B, Luobu G, Ke L, Wu Y. Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial. PLoS One. 2014 Oct 22;9(10):e110131. doi: 10.1371/journal.pone.0110131. eCollection 2014. PubMed 25338053 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Sep 7, 2011
Start
Feb 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Jul 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01429246
Lead sponsor
The George Institute for Global Health, China
Collaborators
Peking University, Beijing Jishuitan Hospital, People's Hospital of Dangxiong County
Responsible party
Sponsor
First posted
Sep 7, 2011
Start date
Feb 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Jul 29, 2016

Study contacts

Yangfeng Wu, PhD
study director · The George Institute, China (Beijing, CN)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salt substitute

Start the discussion